Search

Your search keyword '"Wolf, Douglas A."' showing total 159 results

Search Constraints

Start Over You searched for: Author "Wolf, Douglas A." Remove constraint Author: "Wolf, Douglas A." Publisher elsevier bv Remove constraint Publisher: elsevier bv
159 results on '"Wolf, Douglas A."'

Search Results

1. Surgery for Crohn’s Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts

2. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

4. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)

7. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

11. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program

13. Rethinking chronic toxicity and carcinogenicity assessment for agrochemicals project (ReCAAP): A reporting framework to support a weight of evidence safety assessment without long-term rodent bioassays

14. 885: TRIPLE COMBINATION THERAPY WITH VEDOLIZUMAB, ADALIMUMAB, AND METHOTREXATE IN PATIENTS WITH HIGH-RISK CROHN'S DISEASE: INTERIM ANALYSIS FROM THE OPEN-LABEL, PHASE 4 EXPLORER TRIAL

15. Tu1458: LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

16. 15: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS

17. 653: PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE IMPAIRED HUMORAL BUT PRESERVED CELLULAR RESPONSES TO SARS-COV-2 MRNA VACCINATION

18. Su1547: THE COMBINATION OF PATIENT REPORTED OUTCOMES AND THE ENDOSCOPIC HEALING INDEX IS A GOOD SURROGATE MARKER OF ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH CROHN'S DISEASE

19. 968a: ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

20. 656: POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

23. Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

29. EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS

31. A comprehensive view on mechanistic approaches for cancer risk assessment of non-genotoxic agrochemicals

35. Su1985 ENROLLMENT CHARACTERISTICS OF ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS IN THE CORRONA® INFLAMMATORY BOWEL DISEASE REGISTRY ACCORDING TO TYPE OF INSURANCE

36. An evaluation framework for new approach methodologies (NAMs) for human health safety assessment

39. Tu1733 – Clinical Remission Demonstrated with Oral Ozanimod in the Overall Population and Across Multiple Subgroups of Patients with Moderately to Severely Active Ulcerative Colitis in the Touchstone Trial

41. Chemical carcinogenicity revisited 3: Risk assessment of carcinogenic potential based on the current state of knowledge of carcinogenesis in humans

46. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease

49. Response to Loomis et al Comment on Boobis et al

50. Sustained Remission with Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis: A Gemini 1 Post hoc Analysis of Week 14 Remitters

Catalog

Books, media, physical & digital resources